3). Evidence from clinical trials showed significantly greater sensitivity and higher response rate of BRCA1/2‐associated cancers to neoadjuvant and standard adjuvant chemotherapy than their wild‐type BRCA1/2 counterparts.3 Treatment options for BRCA1/2 breast cancers are also broadened with the introduction of new therapeutic agents, such as poly (ADP‐ribose) polymerase (PARP) inhibitors, which selectively target BRCA1/2‐deficient cancer cells.4, 5, 6, 7. This evidence concerns the gene BRCA1 and cancer.